Journal article
Canadian Clinical Experience on Switching From Standard Half‐life Recombinant Factor VIII (rFVIII), Octocog Alfa, to Extended Half‐life rFVIII, Damoctocog Alfa Pegol, in Persons With Haemophilia A ≥ 12 Years Followed in a Comprehensive Haemophilia Care Program in Canada
Abstract
Authors
Matino D; Chan AKC; Decker K; Iserman E; Edginton AN; Oladoyinbo O; Trinari E; Keepanasseril A; Iorio A
Journal
Haemophilia, Vol. 31, No. 6, pp. 1315–1316
Publisher
Wiley
Publication Date
November 1, 2025
DOI
10.1111/hae.70145
ISSN
1351-8216